The role of magnetic resonance imaging and visual evoked potential in management of optic neuritis

Pan African Medical Journal

Volumn 17, Issue , 2014, Pages 54-

  Al Eajailat, Suha Mikail ^a   Al Madani Sr , Mousa Victor ^b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Optic neuritis; Recurrence; Steroids; Visual evoked potential

Indexed keywords

STEROID; CORTICOSTEROID;

ADOLESCENT; ADULT; AFFERENT PUPILLARY DEFECT; ARTICLE; COLOR VISION DEFECT; DRUG EFFICACY; DRUG RESPONSE; EVOKED VISUAL RESPONSE; EYE PAIN; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; RECURRENT DISEASE; TREATMENT DURATION; VISUAL ACUITY; VISUAL FIELD DEFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OPTIC NEURITIS; PREDICTIVE VALUE OF TESTS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893119164     PISSN: 19378688     EISSN: None     Source Type: Journal    
DOI: 10.11604/pamj.2014.17.54.2462     Document Type: Article

References (16)

1. Hoorbakht H, Bagherkashi F. Optic neuritis, its differential diagnosis and management. Open Ophthalmol J. 2012; 6: 65-72.
2. Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol. 2002; 13(6):375-380.
3. Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol. 2005; 252(4):396-402.
4. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005; 139(6):1101-1108.
5. Brodsky M, Nazarian S, Orengo-Nania S, Hutton GJ, Buckley EG, Massey EW, Bhatti MT, et al. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Optic Neuritis Study Group. Arch Neurol. 2008; 65(6):727-732.
6. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326:581-588.
7. Griffin JF, Wray SH. Acquired color vision defects in retrobulbar neuritis. Am J Ophthalmol. 1978; 86(2):193-201.
8. Shams PN, Plant GT. Optic neuritis: a review. Int MS J. 2009; 16: 82-89.
9. Beck RW, Cleary PA, Optic Neuritis Study Group. Optic Neuritis Treatment Trial: one-year follow-up results. Arch Ophthalmol. 1993; 111(6):773-775.
10. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994; 101(11): 1771-1778.
11. Beck RW, Optic Neuritis Study Group. The Optic Neuritis Treatment Trial. Arch Ophthalmol. http://archopht.jamanetwork.com/article.aspx?articleid=637387. Accessed 24th January 2014.
12. Balcer LJ. Optic Neuritis. Curr Treat Options Neurol. 2001; 3:389-398.
13. Balcer LJ, Galetta SL. Treatment of acute demyelinating optic neuritis. Semin Ophthalmol. 2002; 17(1):4-10.
14. Kaufman DI. Acute Optic Neuritis. Curr Treat Options Neurol. 1999; 1(1):44-48.
15. Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2012; 4:CD001430.
16. Söderström M, Lindqvist M, Hillert J, Käll TB, Link H. Optic neuritis: findings on MRI, CSF examination and HLA class II typing in 60 patients and results of a short-term follow-up. J Neurol. 1994; 241(6):391-397.